Amgen’s Oncology Pipeline Chart
A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with meaningful effects in serious diseases.
Reference: 1. Biernacka A, et al. Cancer Genet. 2016;209:195-198.
Learn about the rapidly evolving landscape of biomarkers in NSCLC, including the KRAS G12C mutation which occurs in 13% of patients with NSCLC.1
Learn about KRAS and KRAS G12C mutations in cancer.
Amgen's CodeBreaK program is actively recruiting patients with the KRAS G12C mutation for studies.
Learn about the mechanism of action and the potential promise of the BiTE® Immuno-Oncology Platform.
This video provides an overview of the role of BCMA in multiple myeloma, as well as the mechanism of action of BCMA-targeted BiTE® molecules.
Listen to a conversation about biomarker testing considerations in the NSCLC landscape.
Watch this video on Minimal Residual Disease (MRD).
Learn all about the MOA of BLINCYTO® in this video.